WO2004082715A8 - 炎症性腸疾患治療剤としての併用医薬 - Google Patents

炎症性腸疾患治療剤としての併用医薬

Info

Publication number
WO2004082715A8
WO2004082715A8 PCT/JP2004/003662 JP2004003662W WO2004082715A8 WO 2004082715 A8 WO2004082715 A8 WO 2004082715A8 JP 2004003662 W JP2004003662 W JP 2004003662W WO 2004082715 A8 WO2004082715 A8 WO 2004082715A8
Authority
WO
WIPO (PCT)
Prior art keywords
compound
inflammatory bowel
therapeutic agent
bowel diseases
bowel disease
Prior art date
Application number
PCT/JP2004/003662
Other languages
English (en)
French (fr)
Other versions
WO2004082715A1 (ja
Inventor
Tatsuo Horizoe
Original Assignee
Eisai Co Ltd
Tatsuo Horizoe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd, Tatsuo Horizoe filed Critical Eisai Co Ltd
Priority to EP04721714A priority Critical patent/EP1607103A1/en
Priority to JP2005503744A priority patent/JPWO2004082715A1/ja
Priority to US10/549,321 priority patent/US20060177444A1/en
Publication of WO2004082715A1 publication Critical patent/WO2004082715A1/ja
Publication of WO2004082715A8 publication Critical patent/WO2004082715A8/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本発明の目的は、潰瘍性大腸炎またはクローン病などの炎症性腸疾患により効果のある医薬を提供することを目的とする。詳しくは、(ａ)活性成分としてアミノサリチル酸誘導体、抗炎症糖質コルチコイド、免疫抑制作用を有する化合物、抗ＴＮＦα抗体、脳下垂体ホルモンおよび抗感染作用を有する化合物からなる群から選ばれる１または２以上の炎症抑制作用を有する化合物と（ｂ）活性成分として１または２以上のＰＰＡＲγアゴニスト作用を有する化合物を組み合わせてなる炎症性腸疾患治療剤であって、化合物（ａ）および化合物（ｂ）を同時に、別々にまたは経時的に使用する、炎症性腸疾患治療剤を提供する。
PCT/JP2004/003662 2003-03-20 2004-03-18 炎症性腸疾患治療剤としての併用医薬 WO2004082715A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04721714A EP1607103A1 (en) 2003-03-20 2004-03-18 Concomitant drug as therapeutic agent for inflammatory bowel disease
JP2005503744A JPWO2004082715A1 (ja) 2003-03-20 2004-03-18 炎症性腸疾患治療剤としての併用医薬
US10/549,321 US20060177444A1 (en) 2003-03-20 2004-03-18 Concomitant drug as therapeutic agent for inflammatory bowel disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003-077467 2003-03-20
JP2003077467 2003-03-20

Publications (2)

Publication Number Publication Date
WO2004082715A1 WO2004082715A1 (ja) 2004-09-30
WO2004082715A8 true WO2004082715A8 (ja) 2005-05-12

Family

ID=33027947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/003662 WO2004082715A1 (ja) 2003-03-20 2004-03-18 炎症性腸疾患治療剤としての併用医薬

Country Status (4)

Country Link
US (1) US20060177444A1 (ja)
EP (1) EP1607103A1 (ja)
JP (1) JPWO2004082715A1 (ja)
WO (1) WO2004082715A1 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200607435B (en) 2004-02-06 2009-05-27 Pharmatel Red Pty Ltd As The T Use of aminosalicylates in diarrhoea-predominant irritable bowel syndrome
US20080306029A1 (en) * 2004-05-28 2008-12-11 Salix Pharmaceuticals, Inc. Prevention, Treatment, and Amelioration of Radiation Induced Enteritis
AU2005249479B2 (en) 2004-05-28 2011-09-15 Salix Pharmaceuticals, Inc. Prevention, treatment, and amelioration of radiation induced enteritis
JP2012021031A (ja) * 2004-10-26 2012-02-02 Salix Pharmaceuticals Inc 放射線誘発性腸炎の予防、処置、および回復
FR2884422B1 (fr) * 2005-04-18 2008-04-11 Roquette Freres Composition anti-inflammatoire de l'intestin comprenant des maltodextrines branchees
JP2007001912A (ja) * 2005-06-22 2007-01-11 Univ Of Tokyo 置換フェニルプロピオン酸誘導体
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
WO2007109088A2 (en) * 2006-03-16 2007-09-27 Metabolic Solutions Development Company Combinationtherapies of thiazolidinedione analogues and glucocorticoid agonists
WO2008108735A1 (en) 2007-03-08 2008-09-12 Albireo Ab 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
RU2486179C2 (ru) * 2007-09-14 2013-06-27 МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи Аналоги тиазолидиндиона для лечения диабета и дислипидемии
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
JP5715070B2 (ja) 2009-02-16 2015-05-07 ノグラ ファーマ リミテッド アルキルアミド化合物およびその使用
EA201290497A1 (ru) * 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
WO2013059410A1 (en) 2011-10-18 2013-04-25 Coherus Biosciences, Inc. Etanercept formulations stabilized with xylitol
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
JP6301844B2 (ja) 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド 線維症の処置方法
US9682050B2 (en) 2012-04-18 2017-06-20 Nogra Pharma Limited Methods of treating lactose intolerance
EA029193B1 (ru) 2012-07-09 2018-02-28 Кохерус Байосайенсис, Инк. Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
EP2895188B1 (en) 2012-09-11 2017-11-15 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
EP3169348B1 (en) * 2014-06-24 2019-07-31 Institut National de la Sante et de la Recherche Medicale (INSERM) Pharmaceutical compositions comprising agonists of orexin-1 receptor ox1r for the treatment of inflammatory bowel diseases
EP3247396A4 (en) 2015-01-20 2018-09-19 Lankenau Institute for Medical Research Methods and compositions for the treatment of diseases and disorders
US11905232B2 (en) 2019-02-08 2024-02-20 Nogra Pharma Limited Process of making 3-(4′-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
TWI311133B (en) * 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof

Also Published As

Publication number Publication date
JPWO2004082715A1 (ja) 2006-06-22
EP1607103A1 (en) 2005-12-21
WO2004082715A1 (ja) 2004-09-30
US20060177444A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
WO2004082715A8 (ja) 炎症性腸疾患治療剤としての併用医薬
WO2006035418A3 (en) Microcapsules comprising a methylxanthine and a corticosteroid
EP1589947B8 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
WO2005117895A8 (en) Compositions comprising meloxicam
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
WO2008011169A3 (en) Controlled release formulations and associated methods
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
CY2013023I2 (el) Φαρμακο για την υπερδραστηρια ουροδοχο κυστη περιλαμβανον παραγωγο ανιλιδιου οξικου οξεοσως το ενεργο συστατικο
WO2004105702A3 (en) Foamable pharmaceutical compositions and methods for treating a disorder
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
WO2008062440A3 (en) Programmable buoyant delivery technology
WO2007032962A3 (en) Compositions and methods for intranasal delivery of tricyclic cannabinoids
IT1289160B1 (it) Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
IL160253A0 (en) Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
PL369671A1 (en) Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
TW200640487A (en) Combination of XOLAIR with immunosuppressive agent
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
WO2005011586A3 (en) Treatment and preventi0n of cardiovascular events
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2006083780A3 (en) Glucuronidated nebivolol
WO2004013153A3 (en) Macrolide compounds endowed with antiinflammatory activity
CA2387486A1 (en) Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
NO20052408D0 (no) Farmasoytisk formulering av olanzapin
WO2004058721A3 (en) Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity
WO2003005967A3 (en) Dual release levodopa ethyl ester and decarboxylase in controlled release core

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 2005503744

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004721714

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006177444

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10549321

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004721714

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10549321

Country of ref document: US